A new dual CAR-T cell therapy has been developed to target T-ALL, showing high efficacy and safety. The treatment targets two antigens simultaneously, making it more effective than previous therapies. Experimental results demonstrate its ability to control the disease in both laboratory and animal models, with an excellent safety profile.
SourceJosep Carreras Leukaemia Research Institute·JournalJournal of Hematology & Oncology·TypeExperimental study·DateJul 7, 2025
Researchers created a powerful cell culture model using induced pluripotent stem cells from a patient with MDS, confirming that the CEBPA mutation drives disease progression. The model could lead to new ways to treat and diagnose MDS and avoid more serious conditions.
SourceUniversity of Birmingham·JournalNature Communications·DateJul 3, 2025
CalDigit TS4 Thunderbolt 4 Dock
CalDigit TS4 Thunderbolt 4 Dock simplifies serious desks with 18 ports for high-speed storage, monitors, and instruments across Mac and PC setups.
Scientists have developed a miniature device that mimics human bone marrow and immune environment, enabling predictive testing of cancer immunotherapy success in patients. The device recreates three regions of bone marrow where leukemia develops and retains the complex immune environment of the tissue.
SourceUniversity of Pennsylvania·JournalNature Biomedical Engineering·TypeExperimental study·DateJul 1, 2025
The study found that the stage of normal cell development at which B cells transform into leukemic cells impacts treatment outcomes for pediatric patients with B-cell acute lymphoblastic leukemia (B-ALL). Researchers identified a 'multipotency score' to predict clinical outcomes, providing valuable insights into drug resistance and str...
SourceSt. Jude Children's Research Hospital·JournalNature Cancer·DateJun 27, 2025
Researchers at Weizmann Institute of Science develop innovative blood test to detect leukemia risk and diagnose age-related conditions like MDS. The test may replace invasive bone marrow sampling procedure.
SourceWeizmann Institute of Science·JournalNature Medicine·DateJun 27, 2025
Researchers at MD Anderson have made significant breakthroughs in cancer treatment, including improved outcomes for elderly patients with IDH-mutant AML who are not eligible for intensive chemotherapy. Additionally, new targeted therapies have been approved as frontline treatments, while pre-surgical radiation therapy may offer an alte...
SourceUniversity of Texas M. D. Anderson Cancer Center·DateJun 26, 2025
SAMSUNG T9 Portable SSD 2TB
SAMSUNG T9 Portable SSD 2TB transfers large imagery and model outputs quickly between field laptops, lab workstations, and secure archives.
A new study reveals that SETD1B plays a critical role in supporting the growth of aggressive acute myeloid leukemia (AML) cells, particularly in those with FLT3-ITD mutations. By targeting SETD1B, researchers believe it may be possible to develop more effective treatments.
SourceChiba University·JournalLeukemia·TypeExperimental study·DateJun 25, 2025
Researchers at the University of Pennsylvania School of Engineering and Applied Science have turned a deadly fungus into a potent cancer-fighting compound. The new compound, called asperigimycins, has shown promising results against leukemia cells, rivaling FDA-approved drugs.
SourceUniversity of Pennsylvania School of Engineering and Applied Science·JournalNature Chemical Biology·TypeExperimental study·DateJun 23, 2025
A Rice University-led research team is working on a new approach to treat acute myeloid leukemia (AML) by targeting the energy-producing mitochondria of cancer cells. By disrupting mitochondrial function, the researchers aim to selectively kill AML cells while leaving healthy blood cells unharmed.
Sky-Watcher EQ6-R Pro Equatorial Mount
Sky-Watcher EQ6-R Pro Equatorial Mount provides precise tracking capacity for deep-sky imaging rigs during long astrophotography sessions.
Researchers developed a dual action immunotherapy using CAR-T cells targeting CD19 and CD22 proteins in B-ALL cancer cells, increasing the efficacy of treatment and reducing relapse rates.
SourceJosep Carreras Leukaemia Research Institute·JournalJournal for ImmunoTherapy of Cancer·TypeExperimental study·DateMay 27, 2025
Charles G. Mullighan, a leading leukemia researcher at St. Jude Children's Research Hospital, has been elected Fellow of the Royal Society. His work on genomic research has advanced the understanding and treatment of acute leukemia in children.
SourceSt. Jude Children's Research Hospital·DateMay 20, 2025
Researchers have developed a new treatment combining venetoclax and inobrodib that shows promising results in killing B-ALL cells, potentially reducing toxic chemotherapy needs. The approach could be less toxic than current treatments and effective in all age groups.
SourceUniversity of Cambridge·JournalNature Communications·TypeExperimental study·DateMay 20, 2025
Apple MacBook Pro 14-inch (M4 Pro)
Apple MacBook Pro 14-inch (M4 Pro) powers local ML workloads, large datasets, and multi-display analysis for field and lab teams.
Researchers at A.C.Camargo Cancer Center developed a more powerful version of CAR-T cells by inhibiting the epigenetic alterations that made them inefficient against non-Hodgkin's lymphoma and acute lymphoblastic leukemia. This modification resulted in improved treatment efficacy, tumor elimination, and reduced side effects.
SourceFundação de Amparo à Pesquisa do Estado de São Paulo·JournalCancer Research·DateMay 19, 2025
A new study published in Genes & Diseases journal introduces a novel therapeutic approach for acute myeloid leukemia (AML) using the METTL3 degrader ZW27941. The research team found that ZW27941 exhibited potent anti-leukemic activity and synergistic effects with existing AML therapies.
SourceCompuscript Ltd·JournalGenes & Diseases·DateMay 7, 2025
Researchers from the University of Southampton engineered a new type of super-strong antibody that triggers a stronger response from the immune system compared to naturally produced antibodies. The study confirms that making subtle increases in rigidity stimulates immune activity, creating a powerful immune response against disease.
SourceUniversity of Southampton·JournalNature Communications·TypeExperimental study·DateMay 1, 2025
A study by UC San Francisco found that children with ALL living in mixed middle- and low-income neighborhoods have a 30-40% higher risk of death. In contrast, AML hospital treatments are shorter, and outpatient visits fewer, reducing challenges for underserved patients.
SourceUniversity of California - San Francisco·JournalCancer·DateApr 30, 2025
Nikon Monarch 5 8x42 Binoculars
Nikon Monarch 5 8x42 Binoculars deliver bright, sharp views for wildlife surveys, eclipse chases, and quick star-field scans at dark sites.
Researchers discover a link between gut health and blood cancer risk, finding that age-related gut changes can accelerate the growth of pre-leukemic blood cells. A specific bacterial sugar, ADP-heptose, plays a key role in this process, and a new blood test detects its activity.
SourceCincinnati Children's Hospital Medical Center·JournalNature·TypeExperimental study·DateApr 23, 2025
Dr Ari Melnick brings extensive experience to the institute, with a focus on precision medicine and haematological diseases. He aims to accelerate innovative treatments and enhance patient outcomes through strong partnerships with leading hospitals and research centres.
SourceJosep Carreras Leukaemia Research Institute·DateApr 22, 2025
A case of therapy-related B-lymphoblastic leukemia (B-ALL) following multiple myeloma treatment is reported, characterized by unusual surface kappa light chain expression. The diagnosis was made based on immunophenotypic analysis and next-generation gene sequencing, which revealed pathogenic mutations in KDM6A and KRAS.
SourceXia & He Publishing Inc.·JournalJournal of Clinical and Translational Pathology·DateApr 10, 2025
Large granular lymphocytic leukemias (LGLLs) are heterogeneous groups of chronic lymphoproliferative disorders. Recent molecular insights and WHO 5th edition updates refine diagnostic precision. T-cell LGLL has favorable prognosis with immunosuppressive treatment, while NK-LGLL is indolent but requires symptomatic treatment.
SourceXia & He Publishing Inc.·JournalJournal of Clinical and Translational Pathology·DateApr 10, 2025
Apple iPad Pro 11-inch (M4)
Apple iPad Pro 11-inch (M4) runs demanding GIS, imaging, and annotation workflows on the go for surveys, briefings, and lab notebooks.
Novel biomarkers like miRNA-34a link anthracyclines to cardiotoxicity, while stem cell therapy and nanotechnology offer potential for prevention and treatment. Traditional strategies have limitations, but new approaches hold hope for improved patient outcomes.
SourceScience China Press·JournalMedicine Plus·DateApr 9, 2025
Researchers have developed drug-delivering aptamers that target and kill leukemia stem cells, reducing the need for high doses of chemotherapy. The aptamers pair well with existing drugs like daunorubicin to deliver a targeted one-two knockout punch against cancer.
SourceUniversity of Illinois at Urbana-Champaign, News Bureau·JournalAdvanced Functional Materials·TypeExperimental study·DateApr 3, 2025
Researchers at Osaka University identify a specific molecule, HLA-DRB1, that can be targeted by CAR-based therapy for AML. Engineered CAR T cells showed strong and specific anti-AML effects in vitro and in vivo with mice, without overt toxicity.
SourceOsaka University·JournalNature Cancer·TypeExperimental study·DateApr 1, 2025
Researchers at Cornell University discovered that the FGR protein can induce cell differentiation in leukemia cells similar to retinoic acid treatment. The presence of FGR alone was enough to make these cells mature, producing well-known markers of maturation and expressing inhibitor of the cell cycle p27.
SourceImpact Journals LLC·JournalOncotarget·TypeNews article·DateMar 31, 2025
Yali Dou, a molecular biologist at Keck School of Medicine of USC, has been elected as an AAAS fellow for her groundbreaking work in understanding leukemia and cancer. Her research on mixed-lineage leukemia proteins has led to the development of potential cancer treatments and a deeper understanding of epigenetics.
Apple iPhone 17 Pro
Apple iPhone 17 Pro delivers top performance and advanced cameras for field documentation, data collection, and secure research communications.
Researchers have developed a TIM-3 decoy that improves the effectiveness of CAR-T cell therapy in treating B-cell Acute Lymphoblastic Leukemia. The decoy blocks the interaction between the tumor and immune cells, allowing CAR-T cells to persist and attack cancer cells more effectively.
SourceCentro Nacional de Investigaciones Oncológicas (CNIO)·JournalBlood·TypeExperimental study·DateMar 24, 2025
Preet Chaudhary and Michael Selsted, USC innovators, recognized by the National Academy of Inventors for their work on harnessing the power of the immune system. Their research aims to develop new treatments for diseases such as cancer, rheumatoid arthritis, and sepsis.
New leukemia treatment combination shows promise for patients with follicular lymphoma. Immunotherapy research also explores ways to suppress protein ZNF638 to boost effectiveness of immune checkpoint inhibitors. Innovative funding efforts support Sylvester's cancer research initiatives.
SourceUniversity of Miami Miller School of Medicine·DateMar 21, 2025
GQ GMC-500Plus Geiger Counter
GQ GMC-500Plus Geiger Counter logs beta, gamma, and X-ray levels for environmental monitoring, training labs, and safety demonstrations.
Researchers have developed a new approach to improve CAR-T cell therapy effectiveness in treating B-cell Acute Lymphoblastic Leukemia. By creating a TIM-3 decoy, they aim to prevent the tumor from turning off the CAR-T cells, leading to improved anti-leukaemia effectiveness and long-term persistence.
SourceJosep Carreras Leukaemia Research Institute·JournalBlood·TypeExperimental study·DateMar 21, 2025
Researchers at Northwestern University have identified a previously unobserved function of Exportin-1, a protein that promotes gene transcription and stimulates stronger gene expression. This discovery could aid in the development of new medications to stymie cancer growth without harming healthy cellular function.
SourceNorthwestern University·JournalMolecular Cell·DateMar 20, 2025
Researchers developed a new diagnostic platform that classifies brain tumors based on the body's cancer-fighting immune response. The approach tailors treatment options to each patient's unique immune profile, offering improved diagnostics and potential for immunotherapies to revolutionize childhood leukemia treatments.
SourceUniversity of Pittsburgh·JournalScience Translational Medicine·DateMar 19, 2025
Researchers developed a microfluidic device to alleviate limitations of conventional blood-filtering machines used in treating hyperleukocytosis in children. The new device separates blood cells by size without platelet loss or adverse effects, enabling safe leukapheresis procedures.
SourceUniversity of Houston·JournalNature Communications·DateMar 19, 2025
Davis Instruments Vantage Pro2 Weather Station
Davis Instruments Vantage Pro2 Weather Station offers research-grade local weather data for networked stations, campuses, and community observatories.
Dr. Owen Witte has been awarded the 12th annual Harrington Prize for Innovation in Medicine for his groundbreaking work on leukemia, lymphoma, and other cancers. His discoveries have led to life-saving therapies like Gleevec and ibrutinib, transforming cancer treatment.
SourceUniversity of California - Los Angeles Health Sciences·DateMar 19, 2025
Researchers at Amsterdam UMC and Moffitt Cancer Center found that contact with CLL cells leads to an energy crisis in T cells, making them unable to proliferate. The study suggests that restoring T cell energy could significantly enhance the effectiveness of current treatments for cancer.
SourceAmsterdam University Medical Center·JournalCellular and Molecular Immunology·TypeRandomized controlled/clinical trial·DateMar 3, 2025
A new study has identified two cell types with distinct biological properties that respond differently to treatment after acquiring the same mutation. Understanding these differences is crucial for developing personalized therapies and preventing aggressive forms of cancer.
SourceInstitute for Research in Biomedicine (IRB Barcelona)·JournalCell Stem Cell·DateFeb 25, 2025
Researchers identified a method to enhance CAR-T cell therapy by modifying the CUL5 gene. This approach improves T cells' growth and longevity, making them more effective in fighting cancer. The study suggests a new way to create targeted cells using a virus to deliver genetic material.
SourceNagoya University·JournalNature Communications·DateFeb 6, 2025
Researchers created a new biologic compound using protein engineering to maximize therapeutic effects while reducing toxicity. The modified enzyme effectively destroyed leukemia cells in mice without common side effects, shrinking tumors in additional cancer models.
GoPro HERO13 Black
GoPro HERO13 Black records stabilized 5.3K video for instrument deployments, field notes, and outreach, even in harsh weather and underwater conditions.
A recent population-based study indicates that among children with cancer, those with obesity at the time of diagnosis may face an elevated risk of dying. The study found a significant negative impact of obesity on prognosis, particularly in patients with acute lymphoblastic leukemia and brain tumors.
Researchers developed a computer model to predict which medication works best for each individual patient with CML. The approach has the potential to improve treatment outcomes for patients who previously relied on stem cell transplantation.
SourceNorwegian University of Science and Technology·JournalPNAS Nexus·TypeComputational simulation/modeling·DateJan 9, 2025
Researchers identified YTHDF2 as a key player in advancing blood cancers, which can help cancer cells evade immune system detection. A new compound CCI-38 targets and suppresses YTHDF2, reducing aggressive blood cancer growth.
SourceCity of Hope·JournalCell·TypeExperimental study·DateDec 17, 2024
Creality K1 Max 3D Printer
Creality K1 Max 3D Printer rapidly prototypes brackets, adapters, and fixtures for instruments and classroom demonstrations at large build volume.
A new blood test developed by RMIT University researchers could help personalize cancer treatments, making them safer and more effective. The test assesses how well different nanomedicines target cancer cells in the blood of leukemia patients, allowing for more tailored therapies.
SourceRMIT University·JournalACS Nano·TypeObservational study·DateDec 16, 2024
A novel study found that the TPMT∗8 allele is associated with reduced metabolism of thiopurine drugs, which can lead to toxicity. The research emphasizes the importance of understanding the function of TPMT∗8 to ensure effective pharmacogenomic testing across all ancestries.
SourceElsevier·JournalJournal of Molecular Diagnostics·TypeExperimental study·DateDec 10, 2024
A global clinical trial has shown a significant improvement in disease-free survival rates for children with B-cell acute lymphoblastic leukemia (B-ALL) by combining standard chemotherapy with blinatumomab, an immunotherapy. The study found improved survival rates of up to 97.5% after three years, compared to 90% with chemotherapy alone.
SourceThe Hospital for Sick Children·JournalNew England Journal of Medicine·DateDec 7, 2024
A comprehensive epigenetic database of over 200 malignant cell lines has been developed, offering valuable insights into leukemia and lymphoma. The database allows researchers to predict drug sensitivity based on epigenetic lesions, aiding in tumour diagnosis and treatment.
SourceJosep Carreras Leukaemia Research Institute·JournalLeukemia·TypeExperimental study·DateNov 26, 2024
MD Anderson researchers have made significant advancements in treating chronic pain, myelodysplastic syndrome, and rare cancers. A novel treatment for chronic pain has been developed with reduced side effects, while targeted therapies like canakinumab show promise for personalized approaches.
SourceUniversity of Texas M. D. Anderson Cancer Center·DateNov 21, 2024
Kestrel 3000 Pocket Weather Meter
Kestrel 3000 Pocket Weather Meter measures wind, temperature, and humidity in real time for site assessments, aviation checks, and safety briefings.
Marina Konopleva joins the Eradicating MRD in AML TeamLab to develop new ways to detect and target Minimal Residual Disease. MECCC has developed multiple targeted agents that have become standard of care for older AML patients, and will partner with Break Through Cancer to deepen understanding of MRD drivers.
The ECOG-ACRIN Cancer Research Group and PrECOG, LLC will present several abstracts at the 66th American Society of Hematology Meeting & Exposition. Promising results from a phase 2 study in acute myeloid leukemia and new data from the practice-changing E1910 phase 3 trial show improved outcomes for patients with B-cell acute lymphobla...
Researchers discover a molecular mechanism controlling PAX5, key regulator of B-cell maturation. Increasing SIRT7 activity may boost PAX5 levels in leukemic cells, inducing cell death.
SourceJosep Carreras Leukaemia Research Institute·JournalNature Immunology·TypeExperimental study·DateOct 21, 2024
A study of over 700 US counties found a link between childhood leukemia and radon gas levels, including those below the EPA's recommended mitigation threshold. Radon exposure increases the likelihood of leukemia in both boys and girls, according to the research.
SourceOregon State University·JournalScience of The Total Environment·TypeData/statistical analysis·DateSep 30, 2024
A study found that children with Down's syndrome have an elevated number of red blood cells, which increases their risk of developing leukemia. The extra chromosome 21 alters DNA packing and gene regulation, contributing to the development of leukemia.
SourceUniversity of Copenhagen - The Faculty of Health and Medical Sciences·JournalNature·DateSep 25, 2024
Aranet4 Home CO2 Monitor
Aranet4 Home CO2 Monitor tracks ventilation quality in labs, classrooms, and conference rooms with long battery life and clear e-ink readouts.
Researchers at St. Jude Children's Research Hospital found that patients with ETV6::RUNX1 and high-hyperdiploid B-ALL can achieve positive outcomes with low-intensity chemotherapy, tailoring treatment based on genetic subtypes and early treatment response. This approach reduces side effects and improves event-free survival rates.
SourceSt. Jude Children's Research Hospital·JournalBlood·DateSep 24, 2024
Scientists at Van Andel Institute and Icahn School of Medicine have developed a potent anti-cancer compound that inhibits cancer cell growth in MLL-rearranged leukemia. MS-41 effectively targets and degrades ENL, a protein essential to the progression of leukemia cells.
SourceVan Andel Research Institute·JournalScience Advances·DateAug 28, 2024
Researchers have found that natural killer cells instinctively recognize and attack the XPO1 protein, which drives cancer growth. By targeting this protein, scientists may be able to activate more killer cells to destroy cancer cells. The study suggests that this approach could lead to personalized cancer treatment with less side effects.
SourceUniversity of Southampton·JournalScience Advances·TypeRandomized controlled/clinical trial·DateAug 28, 2024
Researchers found that approximately 60% of genetic changes driving T-ALL cancer cells are non-coding changes, significantly altering the understanding of disease biology. This leads to innovative treatments, including new immunotherapies developed at CHOP and St. Jude.
SourceSt. Jude Children's Research Hospital·JournalNature·DateAug 14, 2024
Researchers discovered novel genetic variations that influence relapse risk in children with standard-risk B-cell acute lymphoblastic leukemia (SR B-ALL). The study highlights the importance of genomic profiling in accurately determining patient risk and tailoring treatment intensity.
SourceSt. Jude Children's Research Hospital·JournalJournal of Clinical Oncology·DateAug 12, 2024
Celestron NexStar 8SE Computerized Telescope
Celestron NexStar 8SE Computerized Telescope combines portable Schmidt-Cassegrain optics with GoTo pointing for outreach nights and field campaigns.
Scientists at St. Jude Children's Research Hospital identified age-related differences in B-ALL treatment outcomes, with children being more sensitive to certain drugs. The study suggests that both age and individual genomics must be considered to predict treatment response, leading to the need for tailored treatment strategies.
SourceSt. Jude Children's Research Hospital·JournalJournal of Clinical Oncology·TypeExperimental study·DateAug 5, 2024
Infant leukemia with MLL gene rearrangements is resistant to glucocorticoids due to the production of NG2 protein. This leads to FLT3 activation and inactivation of the glucocorticoid receptor, rendering cells insensitive to treatment. The study provides new targets for drug development and immunotherapy.
SourceJosep Carreras Leukaemia Research Institute·JournalBlood·DateAug 5, 2024
Researchers found that type II innate lymphoid cells transform after a cancer patient receives stem cells from a donor, preventing an effective immune system rebuilding. This new understanding may lead to better strategies for enhancing immune system recovery post-transplantation.
SourceUniversity of North Carolina Health Care·JournalNature Communications·TypeExperimental study·DateJul 25, 2024
Rigol DP832 Triple-Output Bench Power Supply
Rigol DP832 Triple-Output Bench Power Supply powers sensors, microcontrollers, and test circuits with programmable rails and stable outputs.
Researchers at the Mayo Clinic Comprehensive Cancer Center discovered a new treatment approach that improved survival rates for patients with B-cell precursor leukemia by nearly 60%. The study found that adding blinatumomab to chemotherapy reduced the risk of leukemia recurrence and death.
SourceMayo Clinic·JournalNew England Journal of Medicine·DateJul 24, 2024
The E1910 trial demonstrated a significant survival advantage with blinatumomab immunotherapy, improving overall and relapse-free survival in patients with BCR::ABL1-negative B-cell precursor acute lymphoblastic leukemia. This finding contributed to the recent FDA approval of blinatumomab for these patients.
SourceECOG-ACRIN Cancer Research Group·JournalNew England Journal of Medicine·TypeRandomized controlled/clinical trial·DateJul 24, 2024